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Identification of differentially 
methylated BRCA1 and CRISP2 
DNA regions as blood surrogate 
markers for cardiovascular disease
Geoffrey Istas1,12, Ken Declerck2, Maria Pudenz3, Katarzyna Szarc vel Szic4, Veronica 
Lendinez-Tortajada5, Montserrat Leon-Latre6,7, Karen Heyninck8, Guy Haegeman8, Jose A. 
Casasnovas7,9,10, Maria Tellez-Plaza11, Clarissa Gerhauser3, Christian Heiss  1, Ana Rodriguez-
Mateos1,12 & Wim Vanden Berghe2,8
Genome-wide Illumina InfiniumMethylation 450 K DNA methylation analysis was performed on blood 
samples from clinical atherosclerosis patients (n = 8) and healthy donors (n = 8) in the LVAD study 
(NCT02174133, NCT01799005). Multiple differentially methylated regions (DMR) could be identified 
in atherosclerosis patients, related to epigenetic control of cell adhesion, chemotaxis, cytoskeletal 
reorganisations, cell proliferation, cell death, estrogen receptor pathways and phagocytic immune 
responses. Furthermore, a subset of 34 DMRs related to impaired oxidative stress, DNA repair, 
and inflammatory pathways could be replicated in an independent cohort study of donor-matched 
healthy and atherosclerotic human aorta tissue (n = 15) and human carotid plaque samples (n = 19). 
Upon integrated network analysis, BRCA1 and CRISP2 DMRs were identified as most central disease-
associated DNA methylation biomarkers. Differentially methylated BRCA1 and CRISP2 regions were 
verified by MassARRAY Epityper and pyrosequencing assays and could be further replicated in blood, 
aorta tissue and carotid plaque material of atherosclerosis patients. Moreover, methylation changes 
at BRCA1 and CRISP2 specific CpG sites were consistently associated with subclinical atherosclerosis 
measures (coronary calcium score and carotid intima media thickness) in an independent sample 
cohort of middle-aged men with subclinical cardiovascular disease in the Aragon Workers’ Health Study 
(n = 24). Altogether, BRCA1 and CRISP2 DMRs hold promise as novel blood surrogate markers for early 
risk stratification and CVD prevention.
According to the World Health Organization (WHO), cardiovascular diseases (CVD) account for the high-
est mortality numbers with approximately 30% of all deaths worldwide (http://www.who.int/gho/ncd/en/). 
Atherosclerosis is the major principle underlying CVDs. At predisposed areas of the vascular tree, including the 
branching points of coronary and carotid arteries, localized accumulation of fatty deposits and inflammation 
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reactions contribute to plaque development and progression eventually leading to impaired blood flow resulting 
in CVDs i.e. coronary artery disease and cerebrovascular disease1.
The development of an atherosclerotic lesion is a slow and silent process making early stage diagnosis diffi-
cult2. Early detection of individuals in the process of developing atherosclerosis might be essential for cardiovas-
cular prevention. Approximately 60% of individuals categorized as at low risk for cardiovascular disease based on 
traditional risk factors prediction equations had subclinical atherosclerosis3, 4. Thus, other factors not traditionally 
included in risk scales are likely to be involved in atherogenesis.
Preclinical evidence supports that aberrant monocyte-macrophage differentiation contributes to vascular wall 
inflammation in patients at high risk for atherosclerosis5, 6. CpG DNA methylation is involved in the epigenetic 
differentiation and regulation of leukocyte specific gene expression profiles, including the expression of soluble 
mediators and surface molecules that direct margination, adhesion, and migration of blood leukocytes in vascu-
lar tissues7. While very little is known about the human leukocyte DNA methylome and its potential causal role 
in cardiovascular disease, blood DNA methylation markers may contribute to the diagnosis of atherosclerosis 
patients. Recent studies have illustrated the feasibility of DNA methylation profiling using peripheral blood to 
identify CVD specific surrogate biomarkers8–15. Candidate-gene approaches identified significant associations 
between leukocyte DNA methylation and atherosclerosis, whereas the results for the association between global 
DNA methylation and atherosclerosis were not always consistent9–12. Previous studies however, evaluated differ-
entially methylated sites using samples from individuals with clinical cardiovascular disease, but did not examine 
the potential role of DNA methylation regions as a marker of subclinical disease.
Therefore, we characterized genome-wide DNA methylation profiles of blood samples of atherosclerosis 
patients versus healthy individuals from the LVAD study (Impact of Left Ventricular Assist Devices Implantation 
on Micro- and Macrovascular Function, (NCT02174133) and identified promising atherosclerosis-related epige-
netic biomarkers. For the selected regions, we validated these whole blood DNA methylation profiles using pub-
licly available Illumina InfiniumMethylation 450 K data from carotid normal and atherosclerotic plaque samples. 
Additionally, we compared CVD associated DNA methylation changes with aging and/or immune cell epigeno-
types. Finally, we explored the role of promising regions as potential predictors of subclinical atherosclerosis in a 
subsample of 24 individuals that participated in the Aragon Workers Health Study (AWHS). The AWHS is a pro-
spective cohort that aims to characterize the factors associated with metabolic abnormalities and imaging-based 
subclinical atherosclerosis measures in a middle-aged population free of clinical cardiovascular disease3, 16.
Results
Peripheral blood of atherosclerosis patients reveals no statistically significant changes in 
global DNA methylation in comparison to healthy individuals. Significant differences in clinical 
parameters were observed between the two study groups. C-reactive protein, haemoglobin concentration and 
triglycerides were significantly lower in the healthy individuals as compared to atherosclerosis patients (Table 1). 
The atherosclerosis patients were generally older than the healthy individuals (Table 1).
DNA methylation profiles covering >450,000 CpG dinucleotides of peripheral blood of eight atherosclerosis 
and eight healthy individuals were generated by Illumina 450k BeadChip arrays. CpG probes were sub-grouped 
in relation to gene regions and to CpG islands to obtain the most comprehensive view of the DNA methyla-
tion distribution in both groups. Global DNA methylation was assessed in each individual by calculating the 
median beta-value of all CpG probes. The mean median values were calculated per sample group (healthy and 
Clinical parameters
Healthy Atherosclerosis
P valueMean ± SD Mean ± SD
Coronary artery 
disease No Yes
Arterial hypertension No Yes
Arrhythmia No Yes
Age 49.7 ± 6.6 78.0 ± 8.4  < 0.0001
BMI (kg/m2) 26.2 ± 2.3 27.0 ± 3.2 0.61
LDL cholesterol  
(mg/dl) 147.4 ± 37.2 121.3 ± 14.5 0.13
HDL cholesterol 
(mg/dl) 52.3 ± 11.2 46.8 ± 10.1 0.41
Total cholesterol 
(mg/dl) 212.7 ± 38.0 179.0 ± 32.5 0.09
Fasting plasma glucose 
(mg/dl) 90.0 ± 8.0 86.1 ± 14.3 0.54
HbA1c (%) 5.7 ± 0.3 5.8 ± 0.9 0.78
CRP (mg/dl) 0.6 ± 0.5 0.7 ± 0.5 0.04
Leukocytes (1000/ul) 6.6 ± 2.3 6.4 ± 1.4 0.84
Hb (mg/dl) 12.7 ± 1.7 14.9 ± 0.6 0.007
Creatinine (mg/dl) 1.0 ± 0.2 1.3 ± 0.5 0.31
Triglycerides (mg/dl) 95.9 ± 44.2 159.5 ± 48.0 0.03
Table 1. Volunteer characteristics. Statistical analysis performed by means of the student T test.
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atherosclerosis). Overall, no statistical significant difference (P-value = 0.9159) was observed in mean global 
DNA methylation between atherosclerosis patients (0.6613, SEM: 0.0067) versus healthy controls (0.6624, SEM: 
0.0071). In addition, no global DNA methylation shifts were found between the groups when mapping cg probes 
to different genomic locations (e.g. CpG islands, shores, shelves) (Supplementary Fig. 1).
Peripheral blood of atherosclerosis patients reveals DNA methylation signature of impaired 
regulation of cell adhesion, chemotaxis and estrogen hormone responses. Criteria for the 
identification of sig-DMPs are summarized in Fig. 1. Normalization, quality control and probe filtering for 
SNPs resulted in an output of 477,044 CpG probes. Differentially methylated CpG probes were filtered for a 
Benjamini-Hochberg adjusted p-value smaller than 0.15 and a difference in β-values between atherosclerosis 
patients and healthy controls of at least 0.05 (i.e. 5% difference in DNA methylation). 712 CpG probes met the 
selection criteria comprising 465 hypomethylated CpG sites (hypo-DMPs) and 247 hypermethylated CpG sites 
(hyper-DMPs) (Fig. 2A, Supplementary Table 2). We observed a maximum of 20% difference in DNA meth-
ylation between atherosclerosis patients and healthy controls. Based on the methylation values of these CpG 
sites, principle component analysis reveals a clear separation of DNA methylation profiles of atherosclerosis 
and healthy individuals (Fig. 2B). Analysis of functional genomic locations using Epi-explorer17 revealed that 
Figure 1. Flowchart of DMP and DMR selection.
Figure 2. Differentially methylated CpG probes between healthy and atherosclerotic individuals. Sig-
DMPs were selected based on FDR < 0.15 and Δ beta >5%. (A) Volcano plot showing 465 hypo- and 247 
hypermethylated probes meeting the selection criteria. (B) PCA plot demonstrating the separation of 
atherosclerosis patients for CVD (grey) and healthy individuals (black) based on the DNA methylation values of 
the 712 DMPs.
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both hyper- and hypo-DMPs were depleted in promoter regions and CpG islands and enriched in intergenic, 
CpG-poor and enhancer regions (Fig. 3).
Since median age of atherosclerosis patients (78 ± 8 years old) and healthy controls (47 ± 8 years old) was 
significantly different (Table 1), we next overlapped our sig-DMP list with the list of age-responsive CpG probes, 
identified by Steengenga et al.18, to discriminate between aging- and atherosclerosis-specific DNA methylation 
changes. Of the 7,477 CpG probes with age-dependent methylation changes, 196 probes overlapped with our 
sig-DMP list, resulting in 516 age-independent DMPs, including 287 hypo- and 229 hyper-DMPs (Supplementary 
Table 2).
To further reduce biological complexity of DNA methylation changes, we next determined consecutive 
sig-DMPs using the R-package DMRcate. In total 236 sig-DMRs were identified (Pmean-value < 0.001) containing 
at least 5 consecutive CpG probes with a minimal DNA methylation difference of 5% (Δβ-value >0.05) (Fig. 1 
and Supplementary Table 3). After overlap with known age-dependent CpG probes18, 75 DMRs were removed 
leaving a total of 161 DMRs (sig-DMRs), containing 1,424 CpG probes, for further analysis. Interestingly, further 
pathway enrichment analysis of the various gene associated DMRs (Supplementary Table 3), identified significant 
(P < 0.05) enrichment of cadherin and integrin dependent cell adhesion, chemotaxis, cytoskeletal reorganisa-
tions, cell cycle and cell death responses, nongenomic estrogen receptor pathways, immune phagocytosis, all of 
which are critically involved in atherosclerosis (Fig. 4 and Supplementary Table 4).
Blood samples of atherosclerosis patients reveal a different immune cell type composition in 
comparison to healthy individuals. Since blood is a heterogeneous collection of different cell types, each 
characterized by unique DNA methylation profile, as recently demonstrated by Jaffe and colleagues19, we next 
wanted to evaluate whether identified DNA methylation changes did not simply reflect variation in blood cell 
composition between both studied populations. Using the algorithm developed by Houseman and colleagues20 for 
mathematical deconvolution of relative immune cell type composition of blood samples based on Illumina 450k 
data21, we observed that the fraction of granulocytes was slightly but statistical significantly (P < 0.05) increased 
in patients at high cardiovascular disease risk in comparison to control individuals (Fig. 5 and Supplementary 
Table 5). In contrast, the CD8+ T-cell population was significantly reduced in atherosclerosis patients. Although 
statistically not significant, a fraction of CD4+ T- and NK-cells tended to decrease in atherosclerosis patient. 
Because of the relative low sample size analysed, we were not able to correct for this in the linear model analysis.
Pathway enrichment analysis of common gene associated DMRs in blood, aorta and carotid 
plaque material reveals impaired NRF2 oxidative stress, DNA repair, thioredoxin and inflam-
matory pathways. In total, 51 cell type-associated DMRs were excluded using the houseman method 
Figure 3. Genomic distribution of sig-DMPs based on (A) gene regions, (B) CpG-island regions and (C) 
chromatin segmentation states (based on GM12878 cell type data). Significant enrichment or depletion of sig-
DMPs (P-value < 0.05), determined by the Fisher’s exact test, are marked by an asterisk.
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leaving 110 sig-DMRs for further analysis. To replicate the potential role for the 110 sig-DMRs as blood-based 
surrogate biomarkers for plaque biopsy material in atherosclerosis, we compared our findings with publicly avail-
able data from Zaina et al. (GSE46401)22 which contains DNA methylation profiles from donor-matched healthy 
and atherosclerotic human aorta tissue and from human carotid plaque samples in a larger independent cohort22. 
We performed a two-tailed student t-test for the 497 CpG probes located in the 110 sig-DMRs comparing meth-
ylation values between donor-matched healthy and aorta plaque tissue and between healthy aorta and carotid 
plaque tissue. We found that 69 CpG probes located in 34 unique DMRs were both consistently differentially 
methylated in our blood-based dataset, in aorta plaque tissue and carotid plaque tissue (Supplementary Table 6). 
Interestingly, pathway enrichment analysis of the 34-common gene associated DMRs revealed Nuclear factor 
(erythroid-derived 2)-like 2 (NRF2), oxidative stress (SOD2), DNA repair (BRCA1), thioredoxin (TXNRD1) 
and inflammatory pathways (MIF, PLA2G4D) (Supplementary Table 7). To find out the relationship between 
the different sig-DMRs, we mapped each sig-DMR to the nearest gene and constructed a network using the 
GeneMANIA Cytoscape plugin (Fig. 6). Interestingly the breast cancer 1 gene (BRCA1) stands out as one of the 
most highly connected node in our network, physically interacting with nine other proteins (Fig. 6). In addition, 
cysteine rich secretory protein 2 (CRISP2), was the gene with the highest node degree. Due to their high network 
interconnectivity (high node degree), BRCA1 and CRISP2 genes were selected for further DNAmethylation bio-
marker validation studies.
Verification of Illumina 450 K DNA methylation intensities of BRCA1 and CRISP2 DMRs by 
Epityper MassARRAY. Differentially methylated regions of BRCA1 and CRISP2 genes determined by 
Illumina 450 array were selected for further technical validation by Epityper MassARRAY. These regions were 
found to be significant using the DMRcate package, having multiple CpG sites with more than 10% difference 
in DNA methylation and showed optimal amplicon fragmentation patterns in Epityper MassARRAY analysis. 
BRCA1 and CRISP2 had the best assay score for MassARRAY analysis, whereas other genes of interest (EID3, 
SDHAP3, TSKS and AURKC) showed limitations in their fragmentation patterns. For BRCA1, we decided to focus 
on 14 consecutive hypermethylated CpG probes located in a CGI (chr17:41,277,974–41,278,445, Supplementary 
Fig. 2). Nine CpG probes in this region showed more than 10% DNA hypermethylation in the atherosclerosis 
patients (cg26370022, cg15065591, cg02286533, cg18372208, cg14947218, cg16006004, cg06001716, cg25288140 
and cg24900425). The CGI is located in an active promoter region (Roadmap Epigenomics Project23). Finally, the 
promoter region of the CRISP2 was selected as a second amplicon for validation. Seven neighboring CpG sites 
(cg26715042, cg14997592, cg04595372, cg01706515, cg25390787, cg08942800 and cg01076129) were found to 
be more than 10% hypermethylated in this region for the atherosclerosis patients. The amplicon covers the entire 
promoter region of the gene (Supplementary Fig. 2). Altogether, the Epityper MassARRAY and Illumina DNA 
methylation levels revealed strongly significant correlations for BRCA1 (ρ = 0.711–0.932) and CRISP2 (ρ = 0.680) 
(Supplementary Fig. 3A). Moreover, BRCA1 and CRISP2 target genes demonstrate significant hypermethylation 
in atherosclerosis blood samples, as compared to blood samples derived from healthy individuals (Fig. 7). Similar 
DNA atherosclerosis associated BRCA1 DNA hypermethylation results were also obtained by pyrosequencing 
of the BRCA1 DMR chr17:41278125–41278228 (including cg26279233, cg cg06001716 and cg cg14947218), 
whereas no valid pyrosequencing assay could be designed for the CRISP2 DMR (Supplementary Fig. 3B and data 
not shown).
Figure 4. Metacore based pathway enrichment analysis of gene associated DMRs in atherosclerosis reveals 
a significant (P-value < 0.05; −log(P-value) < 1.3) enrichment of CVD related pathways related to leukocyte 
chemotaxis and adhesion.
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We further compared the methylation status of the blood cells types in the two validated regions using the 
reference methylation data set of Reinius et al.21. Four CpG probes in the BRCA1 DMR (cg26370022, cg11529738, 
14947218 and cg06001716) (Supplementary Fig. 4) showed significant DNA methylation differences between 
immune cell types (p < 0.05, not corrected for multiple testing). However, after Bonferroni correction hyper-
methylation of only one CpG probe remained significantly correlated with immune cell type (cg26370022). In the 
CRISP2 DMR significant immune cell type specific DNA methylation changes were observed for two CpG probes 
(cg01706515 and cg21710255) (Supplementary Fig. 4). However, observed atherosclerosis related DNA hyper-
methylation trend for most BRCA1 and CRISP2 CpG probes does not follow the expected methylation change in 
blood samples enriched for granulocyte and reduced CD8+ T immune cell subpopulations. As such, our results 
show that DNA hypermethylation of most BRCA1 and CRISP2 CpG probes occurs independently of sample var-
iation in blood cell type composition and is associated with atherosclerosis pathology.
As shown in Fig. 8, the same hypermethylation trend of the BRCA1 and CRISP2 regions could be replicated 
in atherosclerotic tissues from the study by Zaina et al., both in the carotid plaques and the donor-matched aortic 
tissues22. Altogether, our data suggest that BRCA1 and CRISP2 DNA methylation patterns are potential epigenetic 
biomarkers related to atherosclerosis in blood and atherosclerotic plaque tissue matrix.
Association of blood DNA methylation changes in BRCA1 and CRISP2 with subclinical ather-
osclerosis in healthy middle age men of the AWHS cohort. To explore the role of validated regions 
as predictors of subclinical atherosclerosis in a population with a low burden of disease, we evaluated the asso-
ciation of DNA methylation levels from fresh frozen whole blood samples collected at the baseline visit (2009–
2010) and subclinical atherosclerosis measured in 2011–2013 from a subsample of 24 Aragon Workers Health 
Study (AWHS) participants with available baseline InfiniumMethylation 450 K data. We looked for associations 
between blood DNA methylation and the subclinical atherosclerosis measures, coronary calcium score and 
carotid intima media thickness. Associations were found for three CpG probes located in CRISP2 (cg12440062, 
cg25390787, cg01076129) and 1 CpG probe in BRCA1 (cg16630982). The strongest statistically significant CpG 
probe was cg12440062 (located 70 bases upstream of the promotor) for CRISP2, consistently, for both coro-
nary calcium score and carotid intima media thickness measures (Table 2). The multi-adjusted difference in 
coronary calcium score comparing the 75th to the 25th percentiles of DNA methylation was −46.62 score points 
(−86.87, −6.36; p-value = 0.03) for cg12440062 in CRISP2. The corresponding difference in carotid intima media 
thickness was −0.20 millimeters (−0.33, −0.06; p-value = 0.009) for cg12440062 in CRIPS2. For CRISP2, DNA 
methylation in cg01076129 (located in promoter region) was associated with carotid intima-media thickness, 
Figure 5. Deconvolution of immune cell type blood composition. The approach described by Houseman et al. 
was applied to determine the relative immune cell type fraction (Y-axis) in healthy and atherosclerosis blood 
samples. Statistical significant differences in cell type contribution between healthy and atherosclerosis blood 
samples were calculated by a student t-test.
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but not coronary calcium score. The association with cg25390787 (located in promotor region) was only border-
line significant (p = 0.06) consistently for both atherosclerosis measures. With respect to the BRCA1 DMR, the 
strongest association with both coronary calcium score (p-value = 0.018) and carotid intima media thickness 
(p-value = 0.0019) was found for cg16630982 (located in the promotor region), whereas other cg probes did not 
reach significance within the limited sample series tested.
Discussion
In this study, we identified genomic regions in BRCA1 and CRISP2 which were consistently differentially methyl-
ated in blood DNA of atherosclerosis patients compared to healthy individuals, and in aortic and carotid plaque 
Figure 6. GeneMANIA network of the 34 sig-DMRs not affected by age or cell type composition and 
consistently differentially methylated in both blood and plaque tissue.
Figure 7. MassARRAY EpiTYPER validation of BRCA1 and CRISP2. The mean methylation values of each 
measured region are represented in boxplots. The student t-test was used to calculate the significance of the 
methylation difference between healthy and atherosclerotic blood samples.
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samples compared to aorta samples without plaque. Furthermore, methylation in BRCA1 and CRISP2 DMR 
was also associated with subclinical atherosclerosis measures in an independent sample of middle age men. Our 
results thus support a potential role of blood DNA surrogate markers for early CVD detection.
Epigenetics may provide the missing mechanism linking environment, genome and atherosclerotic pheno-
type. Identifying epigenomic biomarkers that parallel the development of subclinical atherosclerosis might open 
new paths for risk stratification and prevention, and may help to further understand the pathophysiology of ather-
osclerosis. In particular, changes in DNA methylation patterns have been linked to several cardiovascular-related 
biomarkers, including homocysteine and C-reactive protein9. Furthermore, an increasing number of studies 
report DNA methylation alterations in atherosclerosis24–26. For example, a recent genome-wide study showed 
Figure 8. DMRs associated with BRCA1 and CRISP2 in an independent publicly available cohort (Zaina  
et al.22). The Zaina et al. cohort comprises of 30 donor-matched atherosclerotic plaque tissue samples and 19 
carotid plaque samples.
CpG probe Gene Difference P75vsP25 (95% CI) P-value
Coronary calcium score
cg16630982 BRCA1 −36.59 (−64.53–−8.64) 0.018
cg12440062 CRISP2 −46.65 (−86.87–−6.36) 0.03
cg25390787 CRISP2 34.98 (−69.35–−0.61) 0.06
Carotid intima thickness
cg16630982 BRCA1 −0.16 (−0.25–−0.07) 0.0019
cg12440062 CRISP2 −0.20 (−0.33–−0.06) 0.009
cg01076129 CRISP2 −0.14 (−0.26–−0.02) 0.036
cg25390787 CRISP2 −0.12 (−0.24−0.00) 0.06
Table 2. Significant associations of BRCA1 and CRISP2 CpG probes with coronary calcium score and carotid 
intima thickness.
www.nature.com/scientificreports/
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DNA methylation differences between healthy donor-matched aortic healthy and plaque tissue, indicated by 
epigenetic drift of DNA methylation in aortic plaques with atherosclerotic progression22, 27. Furthermore, known 
cardiovascular risk factors, including homocysteine levels, smoking and age have been described to induce DNA 
methylation changes28–30. Currently, only few DNA methylation studies have been performed with blood sam-
ples of CAD patients. Sharma et al. identified 72 hypermethylated DMRs associated with CAD and hyperho-
mocysteinemia using a 12k human CpG island microarray31. Guay et al. performed a study on subjects with 
familial hypercholesterolemia with or without CAD using the Infinium 27k methylation array32. Since blood 
leukocytes have major contributions to the initiation, progression and maintenance of atherosclerosis, we deter-
mined genome-wide DNA methylation profiles in blood samples of atherosclerosis patients, in comparison to 
healthy individuals to identify CVD related epigenetic biomarkers. Although Illumina 450 K profiling did not 
reveal significant global DNA methylation differences between atherosclerosis patients and healthy individuals, 
HPLC based methods demonstrated global DNA hypermethylation in blood leukocytes9, 33 whereas both global 
DNA hypermethylation and hypomethylation have been reported in atherosclerotic vascular tissue22, 34, 35.
Upon further mapping of DNA methylation changes at specific CpG motifs or regions, 161 DMRs were identi-
fied to be differentially methylated based on specific selection criteria. Of particular interest, pathway enrichment 
analysis of gene associated DMRs revealed DNA impaired epigenetic regulation of integrin and cadherin depend-
ent cell adhesion, cell cycle, cell death, chemotaxis, immune phagocytosis and estrogen hormone pathways which 
are all critically involved in atherosclerosis. In accordance with other studies examining DNA methylation in 
metabolic diseases, the observed methylation changes were relatively small (max 20%), as compared to cancer 
specific DNA methylation changes. More specifically, whereas promoter regions and CpG islands were found to 
be depleted of atherosclerosis associated DMPs, gene bodies, intergenic and open sea regions show enrichment of 
various DMPs. Interestingly, a strong enrichment was also observed in enhancer regions suggesting that impaired 
control of distal regulatory regions may contribute to atherosclerosis.
Remarkably, mathematical deconvolution (Houseman correction) of the blood DNA methylation profiles 
revealed significant changes in the granulocyte and CD8+ T immune cell populations in atherosclerosis patients 
as compared to healthy individuals, which could be highly relevant for atherosclerotic plaque formation. More 
particularly, important regulatory roles for granulocyte and CD4+/CD8+ T cell populations have recently been 
identified in atherosclerotic lesions and coronary thrombus evolution36, 37. As expected, a large fraction of the 
sig-DMRs were also differentially methylated between blood cell types, suggesting that their change in DNA 
methylation in atherosclerosis patients could be due to a difference in blood cell type composition between ather-
osclerosis and healthy controls. Heterogeneity of blood samples could be prevented using cell count and sorting 
methods (FACS) to analyze specific immune cell subpopulations. However, these methods are difficult and costly 
to apply in large epidemiological cohort studies. CpG sites associated with blood cell type were excluded for fur-
ther analysis, leaving 110 sig-DMRs not affected by blood cell types.
Interestingly, of the 110 remaining DMRs (comprising 497 CpG sites), 34 DMRs (69 CpG sites) were also 
found to be differentially methylated in plaque tissues, which suggests that blood-associated epigenetic biomark-
ers can be valid surrogate markers for methylation changes in plaque material. Of particular interest, pathway 
enrichment analysis of the 34 common gene associated DMRs revealed epigenetic impairment of NRF2 oxidative 
stress (SOD2), DNA repair (BRCA1), thioredoxin (TXNRD1) and inflammatory pathways (MIF, PLA2G4D) in 
atherosclerosis conditions. Upon further network analysis of each sig-DMR, mapped to the nearest gene, we 
identified a highly interconnective network with central roles of BRCA1 and CRISP2 DMRs, which prompted 
us to focus on these genes for further validation. Of special note, the differentially methylated regions in BRCA1 
and CRISP2 appeared to be largely independent of age and/or immune cell type composition, and both hold 
promise as valuable atherosclerosis related biomarkers in routine blood analysis. Interestingly, DNA methylation 
at the BRCA1 locus was already present in healthy controls, which is contrary to other studies where a lack of 
DNA methylation was observed38, 39. Nevertheless, it must be emphasized that the methylated CpGs in our data 
set are located in a CpG island approximately 600 bp upstream of the BRCA1 gene, whereas previous studies40 
detected hypomethylation around the transcription start site of the gene, which can also be appreciated in our 
data (Supplementary Fig. 2).
DNA methylation changes of the BRCA1 and CRISP2 DMRs could also be replicated in an Illumina 450 K 
dataset of paired atherosclerotic plaque and normal aorta samples from 24 middle aged men with subclinical 
atherosclerosis of the Aragon Workers Health Study (AWHS). Moreover, we also observed statistically significant 
association between DNA methylation in several CpG sites in these regions and coronary calcium score and 
carotid intima-media thickness when using data from this well-established population-based cohort3, 16, thus 
adding robustness to our findings. Surprisingly, the associations with subclinical atherosclerosis measures were 
not always directionally consistent compared to the associations comparing blood DNA methylation of cardio-
vascular disease versus healthy individuals or the atherosclerosis versus normal aorta samples. The explanation 
for this inconsistency still remains unclear, although we cannot exclude cell type specific variations in blood sam-
ple composition or complex genotype SNP, microRNA or lncRNA dependent heterogenic epigenetic regulation of 
different BRCA1 or CRISP2 variants41–47. In addition, changes in lifestyle (diet, smoking, pollution, exercise) and 
pharmacological treatments (statins, aspirin, PARP inhibitors) could further obscure DNA methylation changes 
associated with atherosclerosis47, 48.
However, the known biological role of BRCA1 and CRISP2 in cardiometabolic risk and inflammation path-
ways adds further significance to our findings. Besides the well described tumor suppressor function of BRCA1 in 
breast and ovarian cancers, more recent research also demonstrates an important role for BRCA1 in suppression 
of endothelial dysfunction and atherosclerosis49. In the latter study, BRCA1-overexpressing ApoE knock-out mice 
developed significantly less atherosclerotic plaque lesions together with reduced macrophage infiltration and 
diminished ROS production49. In another study, women lacking functional BRCA1/BRCA2 at increased breast 
cancer risk also show greater risk for heart disease and metabolic diseases50–53. BRCA1 is involved in multiple 
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cellular processes and genome stability maintenance like DNA repair, transcriptional regulation, ubiquitination 
and cell-cycle control54. Excessive production of reactive oxygen species, in part via upregulation of DNA damage 
pathways, is a central mechanism governing pathologic activation of vascular smooth muscle cells. Remarkably, 
BRCA1 was found to shield vascular smooth muscle cells (VSMCs) from oxidative stress by inhibiting NADPH 
Nox1-dependent reactive oxygen species production55. More recently, BRCA1 was found to regulate lipogenesis 
through its interaction with acetyl coenzyme A carboxylase56. Along the same line, BRCA1 plays a critical role 
in the regulation of metabolic function in the skeletal muscle where it is involved in lipid storage and insulin 
resistance57. In analogy to BRCA1 dependent suppression of cell motility and epithelial-mesenchymal transition 
in cancer58, BRCA1 may also prevent endothelial-mesenchymal transition involved in atherosclerosis progression 
and other CVDs (myocardial infarction, vascular calcification)59–61. As our data suggests, silencing of the BRCA1 
gene in atherosclerosis patients may mean that this gene not only acts a tumor suppressor but also as a vascular 
protector against oxidative cell damage.
While no CRISP2 functions have so far been reported in relation to CVDs, CRISP2 gene activities were 
recently associated with oxidative stress responses and decline of lung function upon smoke or particular matter 
exposure62. In another study, CRISP expression was found to abolish the neovascularization process induced by 
exogenous growth factors (bFGF, vpVEGF)63. Decreased CRISP2 expression correlated with Th2-like eosino-
philic inflammation in chronic nasal asthmatic chronic rhinosinusitis64. As such, the potential involvement of 
CRISP2 in CVD pathologies and angiogenesis via oxidative stress and inflammatory responses warrants further 
investigation.
An important limitation in our study is reflected by the small sample size of the studied samples, which ren-
ders our analysis clearly underpowered. Future prospective studies in larger and distinct cohorts could further 
enable the validation of BRCA1 and CRISP2 to predict early cardiovascular disease. Additionally, the atheroscle-
rosis patients were older than the healthy controls. Even though, a correction for age-specific methylation was 
performed, we cannot exclude that age may affect the results and is therefore a confounding factor. In addition, 
as atherosclerosis is an age-dependent disease, probably some of the excluded age-dependent CpG sites overlap 
with CDV related CpGs. Nonetheless, in the post-hoc analysis with the Aragon Workers Health Study, a study 
population composed of cardiovascular disease free middle age men, the main findings were consistent even after 
adjustment of age, BMI, smoking and houseman cell composition. While we cannot discard a potential lack of 
generalizability, which is typical of observational studies, an important strength of our study includes the availa-
bility of DNA-methylation data from three independent set of samples covering the whole spectrum from blood 
samples from individuals with subclinical atherosclerosis measures and individuals at high and low cardiovascu-
lar risk to carotid and aorta samples.
In conclusion, we identified promising novel epigenetic biomarkers of clinical and subclinical atheroscle-
rotic disease, in genes involved in impaired leukocyte-endothelium functions during atherosclerosis progression. 
These regions deserve further consideration in experimental studies and prospective population-based cohort to 
confirm their potential role in cardiovascular risk. If confirmed, the reported markers could become potential 
tools to support early identification of individuals at high CVD risk who could benefit from preventive interven-
tions for cardiovascular disease prevention and control.
Methods
We fist conducted a discovery phase analysis of DNA methylation data from 8 healthy voluntaries and 8 patients 
with atherosclerosis from the Study “Impact of Left Ventricular Assist Devices Implantation on Micro- and 
Macrovascular Function” (LVAD study, clinicaltrials.gov: NCT02174133). Subsequently we validated findings 
from the discovery phase by analyzing DNA methylation data from plaque material related to GEO dataset 
GSE46401 published by Zaina et al. Finally, as a post-hoc analysis, we explored the potential role of the identified 
markers as early detection biomarkers by evaluating the association of DNA methylation and subclinical ather-
osclerosis endpoints in whole blood DNA from 24 Aragon Workers Study participants free of clinical cardiovas-
cular disease.
Experimental set-up and sample collection in the discovery stage. In the LVAD study, eight 
healthy volunteers were recruited based on following inclusion criteria: age (35–60 years), BMI (23–27 kg/m²), 
average physical activity and normal western diet (clinicaltrials.gov: NCT01799005). The exclusion criteria for 
the healthy volunteers were CVD, diabetes mellitus, acute inflammation and arrhythmia. We additionally selected 
eight patients with confirmed clinical diagnosis of atherosclerosis (clinicaltrials.gov: NCT02174133). The charac-
teristics of the study population are described in Table 1. Whole blood (0.5 ml) was collected from all individuals, 
following informed consent. The study was conducted according to the guidelines laid down in the Declaration 
of Helsinki and all procedures involving human subjects were approved by the University of Düsseldorf Research 
Ethics Committee (ref: 3870 and ref: 4565R).
Infinium HumanMethylation450 BeadChip Array processing and data analysis for whole blood 
DNA from atherosclerosis patients and healthy donors. Genomic DNA (gDNA) isolated from 0.5 ml 
whole blood (EDTA), was isolated with DNeasy Blood & Tissue kit (Qiagen Hilden, Germany) and quantified by 
Nanodrop™ spectrophotometry. 1000 ng of gDNA was bisulfite converted using the EZ DNA methylation kit 
(Zymo Research, Orange, CA, USA) according to manufacturer’s instructions. Genome-wide DNA methylation 
was analyzed on Infinium HumanMethylation450 BeadChip platform (Illumina, San Diego, CA, USA) at the 
DKFZ Genomics and Proteomics Core Facility. 4 µl of bisulfite-converted whole blood DNA (~150 ng) was used 
for the whole genome amplification (WGA) reaction, enzymatic fragmentation, precipitation and re-suspended 
in hybridization buffer. Subsequent steps of DNA methylation analysis were carried out according to the standard 
Infinium HD Assay Methylation Protocol Guide (Part #15019519, Illumina). The BeadChip images were captured 
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using the Illumina iScan. Pre-processing and analysis of the Infinium 450k data was performed using the R pack-
age RnBeads65. CpG probes containing a SNP at least 3 bp from the 3’ query site, having a detection p-value 
higher than 0.01, having empty values in at least one sample or measuring methylation in a non-CpG context 
were removed. In total 8,533 CpG probes (1.75%) were filtered. Intra-array normalization was done using the 
Beta Mixture Quantile Normalization66. Methylation values were represented as β-values ranging from 0 to 1. 
β-alues were converted into M-values = β
β−( )( )M log2 (1 ) before doing the statistical analysis. Limma R pack-
age was used to identify differentially methylated positions. Raw p-values were corrected for multiple testing 
using the Benjamini-Hochberg method. CpG probes with an adjusted p-value below 0.15 and having a difference 
in β-values of at least 0.05 (i.e. 5% difference in DNA methylation) between atherosclerosis patients and healthy 
controls were denoted as significant, and named sig-DMPs. Differentially methylated regions were identified 
using the DMRcate R package67. A region was called significant when Pmean-value was below 0.001 with a max-
imum methylation difference of at least 5% and containing at least five CpGs. Sig-DMPs were annotated using the 
HumanMethylation450 v1.2 manifest file. The freely available EpiExplorer tool was used to add further annota-
tion including chromatin state segmentation and histone modifications17. Enrichment or depletion of sig-DMPs 
in a particular genomic region was determined using the Fisher’s exact test. Commercial Metacore (https://portal.
genego.com/)and Ingenuity (www.ingenuity.com/) software packages werre used to identify significant pathway 
enrichment of gene associated DMRs.
The method of Houseman et al.20 incorporated in the RnBeads package was used to estimate the cell type 
composition in blood. Reference cell types for granulocytes, CD4+ T-cells, CD8+ T-cells, B-cells, monocytes and 
NK-cells were obtained from the study of Reinius et al.21 using the FlowSorted.Blood.450k R package. The meth-
ylation profiles were processed (filtering and normalization) together with the atherosclerosis methylation dataset 
in the same way as described above. In total 50,000 CpG probes with the highest variance were used to identify 
the top 500 CpG probes associated with the cell types. The relative cell type contributions were compared between 
healthy individuals and atherosclerosis using a normal student t-test. One-way ANOVA and Bonferroni Post-hoc 
test was used to detect methylation differences between the blood cell types using the data from Reinius et al.
Replication in atherosclerotic plaque material methylation dataset GSE46401. Normalized 
Infinium 450k DNA methylation data of atherosclerotic plaque material were obtained from GEO dataset 
GSE46401. The dataset contains data from 15 donor-matched aorta healthy and plaque tissue and from 19 carotid 
plaque material. A paired two-tailed student t-test was performed to find DNA methylation differences in the 
15 donor-matched samples and an unpaired two-tailed student t-test was performed to find DNA methylation 
differences between the carotid plaque tissue samples and the healthy aorta samples.
Epityper Sequenom MassARRAY. In silico cleavage was done by means of the RSeqMeth script in R to 
aid selection of an optimal primer set for the genomic region of interest68. MassARRAY primers for regions in the 
BRCA1 (chr17:41,277,701–41,278,776) and CRISP2 (chr6:49,680,757–49,682,289) genes (Supplementary Table 1 
and Supplementary Fig. 2) were designed using the Sequenom EpiDesigner online tool (www.epidesigner.com). 
Bisulfite converted DNA was used for the methylation analysis. PCR reactions were performed using the follow-
ing reagents: 10x buffer (Qiagen®), 10 mM dNTP, 10 µM primer mix, 5 U/µl HotStarTaqTM polymerase (Qiagen®) 
and deionized water. Methylation percentages were calculated based on the ratio of the unmethylated versus 
methylated peaks. In addition, DNA methylation standards (0, 20, 40, 60, 80 and 100%) were used to control for 
amplification bias. The R computing environment was used for the correction of the obtained methylation data 
according to standard procedures69. Linear regression was performed to fit the obtained data points according to 
the predicted standard methylation values. The student T-test was used to calculate the significance of the meth-
ylation difference between healthy and atherosclerotic blood samples.
Pyrosequencing. 1 µg gDNA from each sample was bisulfite converted using the EpiTect Fast bisulfite con-
version kit (Qiagen, Hilden, Germany) according to manufacturer’s instructions. 15 ng of bisulfite treated DNA 
was subsequently used in PCR amplification using the PyroMark PCR kit (Qiagen, Hilden, Germany). Reverse 
primers were biotinylated to get biotin-labelled PCR products. Finally, DNA sequences were pyrosequenced 
using the PyroMark Q24 Advanced instrument (Qiagen, Hilden, Germany). First, streptavidin-coated Sepharose 
beads (High Performance, GE Healthcare, Uppsala, Sweden) were used to immobilize the biotin-labelled PCR 
products. Subsequently, PCR products were captured by the PyroMark vacuum Q24 workstation, washed and 
denaturated. The single stranded PCR products were mixed and annealed with their corresponding sequencing 
primer. After the pyrosequencing run was finished, the results were analysed using the PyroMark Q24 Advanced 
software (Qiagen, Hilden, Germany). Biotinylated-reverse, forward and sequencing primers were designed using 
the PyroMark assay design 2.0 software (Qiagen, Hilden, Germany) (Supplementary Table 1).
Post-hoc analysis of human blood DNA methylation in BRCA1 and CRISP2 and subclinical ath-
erosclerosis in middle-age healthy men. The Aragon Workers Health Study (AWHS) is a study designed 
to assess cardiovascular risk and subclinical atherosclerosis in a cohort of middle-aged healthy men from Spain. 
The AWHS design and baseline characteristics have been reported elsewhere3, 16. In brief, in the baseline exami-
nation (2009–2010), the average (SD) age, body mass index, and waist circumference were 49.3 (8.7) years, 27.7 
(3.6) kg/m2 and 97.2 (9.9) cm, respectively, The prevalence of overweight, obesity, current smoking, hyperten-
sion, hypercholesterolemia, and diabetes were 55.0, 23.1, 37.1, 40.3, 75.0, and 7.4%, respectively70. The adherence 
of the AWHS participants to the Mediterranean diet has been extensively studied71. 21.7% of participants in the 
AWHS reported being physical active (e,g, >150 min/week or 30 min/d of jogging, walking quickly, dance, aero-
bics, gardening)71. The levels of physical activity were positively associated with the adherence to the Mediterrean 
lifestyle71. In 2011–2013, calcium coronary scoring was performed using non-contrast ECG gated prospective 
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acquisition by a 16 multidetector computed tomography scanner (Mx 8000 IDT 16, Philips Medical Systems, 
Best, the Netherlands). During a single breath hold, images were acquired from the tracheal bifurcation to below 
the base of the heart. Scan parameters were 8 × 3 mm collimation, 220-mm field of view, 120 kVp, 55 mA, and 
3-mm section thickness. Coronary calcium was quantified with calcium scoring software (Workspace CT viewer, 
Philips Medical Systems) that follows the Agatston method72. Carotid intima-media thickness was determined 
using the Philips IU22 ultrasound system (Philips Healthcare, Bothell, Washington). Ultrasound images were 
acquired with linear high-frequency 2-dimensional probes (Philips Transducer L9–3, Philips Healthcare), follow-
ing the Bioimage Study protocol73. Examination of the carotid territory included the terminal portion (10 mm) 
of the common carotid, the bulb, and the initial portion (10 mm) of the internal and external carotid arteries. The 
given value for carotid artery intima-media thickness is the mean value from all sites at both sides. The AWHS 
study was approved by the Ethics Committee for Clinical Research at the Institutional Review Board of Aragón 
(CEICA)3, 16. All study participants provided written informed consent. The methods for DNA isolation and 
bisulfite conversion were similar to the methods implemented in the LVAD samples, which are standard manu-
facturer procedures. DNA methylation was measured using the platform Illumina Infinium Methylation 450 K in 
a subsample of 23 individuals with available measures of subclinical atherosclerosis. Preprocessing and analysis of 
the Infinium 450k data was performed using the R package minfi74. CpG probes with a detection p-value higher 
than 0.01 were removed. Intra-array normalization was done using the Quantile Normalization. In exploratory 
analysis, we detected a potential batch effect by slide. Methylation proportion values were represented as β-values 
ranging from 0 to 1. β-values were converted into M-values before doing the statistical analysis. For analysis 
of site-specific DNA methylation (independent variable) and subclinical atherosclerosis measures (dependent 
variable) in the AWHS, we estimated the differences in coronary artery score and carotid intima media thickness 
comparing 75th versus 25th percentiles of DNA methylation distribution at a given CpG site by linear regression 
with the following adjustment variables: age, smoking status (never, former and current smoking), body mass 
index, and houseman cell estimates (B cell, CD4+ and CD8+ T cells, granulocytes, monocytes and natural killer 
cells). Due to the small sample size we tried to avoid non-parsimonious regression parameters by performing 
two-stage regression for adjustment. First we adjusted DNA methylation M-values for potential confounders 
using combat75 to correct for batch effect by slide. Subsequently, we adjusted intima media thickness and coronary 
artery calcium score levels for the same set of potential confounders. Second, we ran the final regression models 
using the residuals resulting from the first step recalibrated to the corresponding marginal mean. Since this was 
post-hoc analysis we evaluated the association of DNA methylation and subclinical atherosclerosis in CpG sites 
from regions validated in previous analysis (i.e. BRCA1 and CRISP2). Thus, we considered the non-Bonferroni 
corrected p-values < 0.05 as statistically significant.
Availability of data. Data are available on request. DNA methylation data will be deposited in the GEO 
profile database.
Ethics approval and consent to participate. The study was conducted according to the guidelines laid 
down in the Declaration of Helsinki and all procedures involving human subjects were approved by the University 
of Düsseldorf Research Ethics Committee (ref: 3870 and ref: 4565 R). The Aragon Workers Health Study partic-
ipants (AWHS) study was approved by the Ethics Committee for Clinical Research at the Institutional Review 
Board of Aragón (CEICA)3, 16. All study participants provided written informed consent.
References
 1. Kwon, G. P., Schroeder, J. L., Amar, M. J., Remaley, A. T. & Balaban, R. S. Contribution of macromolecular structure to the retention 
of low-density lipoprotein at arterial branch points. Circulation 117, 2919–27 (2008).
 2. Fernández-Ortiz, A. et al. The Progression and Early detection of Subclinical Atherosclerosis (PESA) study: rationale and design. 
Am. Heart J. 166, 990–8 (2013).
 3. Laclaustra, M. et al. Femoral and Carotid Subclinical Atherosclerosis Association With Risk Factors and Coronary Calcium: The 
AWHS Study. J. Am. Coll. Cardiol. 67, 1263–1274 (2016).
 4. Fernández-Friera, L. et al. Prevalence, Vascular Distribution, and Multiterritorial Extent of Subclinical Atherosclerosis in a Middle-
Aged Cohort: The PESA (Progression of Early Subclinical Atherosclerosis) Study. Circulation 131, 2104–13 (2015).
 5. Ginhoux, F. & Jung, S. Monocytes and macrophages: developmental pathways and tissue homeostasis. Nat. Rev. Immunol. 14, 
392–404 (2014).
 6. Xue, J. et al. Transcriptome-based network analysis reveals a spectrum model of human macrophage activation. Immunity 40, 
274–88 (2014).
 7. Wang, J. et al. Hyperhomocysteinemia-Induced Monocyte Chemoattractant Protein-1 Promoter DNA Methylation by Nuclear 
Factor-κB/DNA Methyltransferase 1 in Apolipoprotein E-Deficient Mice. Biores. Open Access 2, 118–27 (2013).
 8. Levenson, V. V. & Melnikov, A. A. DNA methylation as clinically useful biomarkers-light at the end of the tunnel. Pharmaceuticals 
(Basel). 5, 94–113 (2012).
 9. Sharma, P. et al. Detection of altered global DNA methylation in coronary artery disease patients. DNA Cell Biol. 27, 357–65 (2008).
 10. Baccarelli, A. et al. Ischemic heart disease and stroke in relation to blood DNA methylation. Epidemiology 21, 819–28 (2010).
 11. Kim, M. et al. DNA methylation as a biomarker for cardiovascular disease risk. PLoS One 5, e9692 (2010).
 12. Cash, H. L. et al. Cardiovascular disease risk factors and DNA methylation at the LINE-1 repeat region in peripheral blood from 
Samoan Islanders. Epigenetics 6, 1257–64 (2011).
 13. Huang, Y.-S., Zhi, Y.-F. & Wang, S.-R. Hypermethylation of estrogen receptor-alpha gene in atheromatosis patients and its 
correlation with homocysteine. Pathophysiology 16, 259–65 (2009).
 14. Jiang, D. et al. Elevated PLA2G7 gene promoter methylation as a gender-specific marker of aging increases the risk of coronary heart 
disease in females. PLoS One 8, e59752 (2013).
 15. Guay, S.-P. et al. ABCA1 gene promoter DNA methylation is associated with HDL particle profile and coronary artery disease in 
familial hypercholesterolemia. Epigenetics 7, 464–72 (2012).
 16. Casasnovas, J. A. et al. Aragon workers’ health study–design and cohort description. BMC Cardiovasc. Disord. 12, 45 (2012).
 17. Halachev, K., Bast, H., Albrecht, F., Lengauer, T. & Bock, C. EpiExplorer: live exploration and global analysis of large epigenomic 
datasets. Genome Biol. 13, R96 (2012).
www.nature.com/scientificreports/
13Scientific RepoRts | 7: 5120  | DOI:10.1038/s41598-017-03434-0
 18. Steegenga, W. T. et al. Genome-wide age-related changes in DNA methylation and gene expression in human PBMCs. Age (Dordr). 
36, 9648 (2014).
 19. Jaffe, A. E. & Irizarry, R. A. Accounting for cellular heterogeneity is critical in epigenome-wide association studies. Genome Biol. 15, 
R31 (2014).
 20. Houseman, E. A. et al. DNA methylation arrays as surrogate measures of cell mixture distribution. BMC Bioinformatics 13, 86 
(2012).
 21. Reinius, L. E. et al. Differential DNA methylation in purified human blood cells: implications for cell lineage and studies on disease 
susceptibility. PLoS One 7, e41361 (2012).
 22. Zaina, S. et al. DNA methylation map of human atherosclerosis. Circ. Cardiovasc. Genet. 7, 692–700 (2014).
 23. Dunham, I. et al. An integrated encyclopedia of DNA elements in the human genome. Nature 489, 57–74 (2012).
 24. Zaina, S. Unraveling the DNA methylome of atherosclerosis. Curr. Opin. Lipidol. 25, 148–53 (2014).
 25. Wierda, R. J., Geutskens, S. B., Jukema, J. W., Quax, P. H. A. & van den Elsen, P. J. Epigenetics in atherosclerosis and inflammation. 
J. Cell. Mol. Med. 14, 1225–40 (2010).
 26. Udali, S., Guarini, P., Moruzzi, S., Choi, S.-W. & Friso, S. Cardiovascular epigenetics: from DNA methylation to microRNAs. Mol. 
Aspects Med. 34, 883–901.
 27. Valencia-Morales, M. del P. et al. The DNA methylation drift of the atherosclerotic aorta increases with lesion progression. BMC 
Med. Genomics 8, 7 (2015).
 28. Zhou, S., Zhang, Z. & Xu, G. Notable epigenetic role of hyperhomocysteinemia in atherogenesis. Lipids Health Dis. 13, 134 (2014).
 29. Breitling, L. P. Current genetics and epigenetics of smoking/tobacco-related cardiovascular disease. Arterioscler. Thromb. Vasc. Biol. 
33, 1468–72 (2013).
 30. Terry, M. B., Delgado-Cruzata, L., Vin-Raviv, N., Wu, H. C. & Santella, R. M. DNA methylation in white blood cells: association with 
risk factors in epidemiologic studies. Epigenetics 6, 828–37 (2011).
 31. Sharma, P. et al. Genome wide DNA methylation profiling for epigenetic alteration in coronary artery disease patients. Gene 541, 
31–40 (2014).
 32. Mathieu, P. & Bouchard, L. A study in familial hypercholesterolemia suggests reduced methylomic plasticity in men with coronary 
artery disease. 7, 17–34 (2015).
 33. Kim, M. et al. DNA methylation as a biomarker for cardiovascular disease risk. PLoS One 5, e9692 (2010).
 34. Aavik, E. et al. Global DNA methylation analysis of human atherosclerotic plaques reveals extensive genomic hypomethylation and 
reactivation at imprinted locus 14q32 involving induction of a miRNA cluster. Eur. Heart J. ehu437–, doi:10.1093/eurheartj/ehu437 
(2014).
 35. Hiltunen, M. O. et al. DNA hypomethylation and methyltransferase expression in atherosclerotic lesions. Vasc. Med. 7, 5–11 (2002).
 36. Spitz, C. et al. Regulatory T cells in atherosclerosis: critical immune regulatory function and therapeutic potential. Cell. Mol. Life Sci. 
doi:10.1007/s00018-015-2080-2 (2015).
 37. Li, X. et al. Granulocytes in coronary thrombus evolution after myocardial infarction - time-dependent changes in expression of 
matrix metalloproteinases. Cardiovasc. Pathol., doi:10.1016/j.carpath.2015.09.007 (2015).
 38. Zhang, L. & Long, X. Association of BRCA1 promoter methylation with sporadic breast cancers: Evidence from 40 studies. Sci. Rep. 
5, 17869 (2015).
 39. Sharma, P. et al. The prognostic value of BRCA1 promoter methylation in early stage triple negative breast cancer. J. Cancer Ther. Res. 
3, 2 (2014).
 40. Zhang, L. & Long, X. Association of BRCA1 promoter methylation with sporadic breast cancers: Evidence from 40 studies. Sci. Rep. 
5, 17869 (2015).
 41. Wallace, A. J. New challenges for BRCA testing: a view from the diagnostic laboratory. Eur. J. Hum. Genet. 24, 10–18 (2016).
 42. Diederichs, S. et al. The dark matter of the cancer genome: aberrations in regulatory elements, untranslated regions, splice sites, 
non-coding RNA and synonymous mutations. EMBO Mol. Med. 8, 442–57 (2016).
 43. Chehade, R. et al. Reduced BRCA1 transcript levels in freshly isolated blood leukocytes from BRCA1 mutation carriers is mutation 
specific. Breast Cancer Res. 18, 87 (2016).
 44. Beroud, C. et al. BRCA Share: A Collection of Clinical BRCA Gene Variants. Hum. Mutat. doi:10.1002/humu.23113 (2015).
 45. Lo, P.-K. et al. Dysregulation of the BRCA1/long non-coding RNA NEAT1 signaling axis contributes to breast tumorigenesis. 
Oncotarget doi:10.18632/oncotarget.11364 (2014).
 46. Daniels, S. L. et al. Levels of DNA Methylation Vary at CpG Sites across the BRCA1 Promoter, and Differ According to Triple 
Negative and &quot;BRCA-Like&quot; Status, in Both Blood and Tumour DNA. PLoS One 11, e0160174 (2016).
 47. Papoutsis, A. J., Selmin, O. I., Borg, J. L. & Romagnolo, D. F. Gestational exposure to the AhR agonist 2,3,7,8-tetrachlorodibenzo-p-
dioxin induces BRCA-1 promoter hypermethylation and reduces BRCA-1 expression in mammary tissue of rat offspring: preventive 
effects of resveratrol. Mol. Carcinog. 54, 261–9 (2015).
 48. Lecht, S. et al. Anti-angiogenic activities of snake venom CRISP isolated from Echis carinatus sochureki. Biochim. Biophys. Acta 
1850, 1169–79 (2015).
 49. Singh, K. K. et al. BRCA1 is a novel target to improve endothelial dysfunction and retard atherosclerosis. J. Thorac. Cardiovasc. Surg. 
146, 949–960 (2013).
 50. Singh, K. K. et al. BRCA2 Protein Deficiency Exaggerates Doxorubicin-induced Cardiomyocyte Apoptosis and Cardiac Failure. J. 
Biol. Chem. 287, 6604–6614 (2011).
 51. Moreau, K. et al. BRCA1 affects lipid synthesis through its interaction with acetyl-CoA carboxylase. J. Biol. Chem. 281, 3172–3181 
(2006).
 52. Shukla, P. C. et al. BRCA1 is an essential regulator of heart function and survival following myocardial infarction. Nat. Commun. 2, 
593 (2011).
 53. Bordeleau, L. et al. Diabetes and breast cancer among women with BRCA1 and BRCA2 mutations. Cancer 117, 1812–1818 (2011).
 54. Greenberg, R. A. Recognition of DNA double strand breaks by the BRCA1 tumor suppressor network. Chromosoma 117, 305–17 
(2008).
 55. Lovren, F. et al. BRCA1 shields vascular smooth muscle cells from oxidative stress. J. Thorac. Cardiovasc. Surg. 147, 1946–55 (2014). 
1955.e1.
 56. Moreau, K. et al. BRCA1 Affects Lipid Synthesis through Its Interaction with Acetyl-CoA Carboxylase. J. Biol. Chem. 281, 3172–3181 
(2005).
 57. Jackson, K. C. et al. BRCA1 is a novel regulator of metabolic function in skeletal muscle. J. Lipid Res. 55, 668–680 (2014).
 58. Bai, F. et al. BRCA1 suppresses epithelial-to-mesenchymal transition and stem cell dedifferentiation during mammary and tumor 
development. Cancer Res. 74, 6161–72 (2014).
 59. Chen, P.-Y. et al. Endothelial-to-mesenchymal transition drives atherosclerosis progression. J. Clin. Invest. 2015 (2015).
 60. Ma, K. L. et al. Inflammatory stress exacerbates the progression of cardiac fibrosis in high-fat-fed apolipoprotein E knockout mice 
via endothelial-mesenchymal transition. Int. J. Med. Sci. 10, 420–6 (2013).
 61. von Gise, A. & Pu, W. T. Endocardial and epicardial epithelial to mesenchymal transitions in heart development and disease. Circ. 
Res. 110, 1628–45 (2012).
 62. Curjuric, I. et al. Different genes interact with particulate matter and tobacco smoke exposure in affecting lung function decline in 
the general population. PLoS One 7, e40175 (2012).
www.nature.com/scientificreports/
1 4Scientific RepoRts | 7: 5120  | DOI:10.1038/s41598-017-03434-0
 63. Lecht, S. et al. Anti-angiogenic activities of snake venom CRISP isolated from Echis carinatus sochureki. Biochim. Biophys. Acta - 
Gen. Subj 1850, 1169–1179 (2015).
 64. Plager, D. A. et al. Gene transcription changes in asthmatic chronic rhinosinusitis with nasal polyps and comparison to those in 
atopic dermatitis. PLoS One 5, e11450 (2010).
 65. Assenov, Y. et al. Comprehensive Analysis of DNA Methylation Data With RnBeads. http://rnbeads.mpi-inf.mpg.de (2014).
 66. Teschendorff, A. E. et al. A beta-mixture quantile normalization method for correcting probe design bias in Illumina Infinium 450 
k DNA methylation data. Bioinformatics 29, 189–96 (2013).
 67. Peters, T. J. et al. De novo identification of differentially methylated regions in the human genome. Epigenetics Chromatin 8, 6 (2015).
 68. Coolen, M. W., Statham, A. L., Gardiner-Garden, M. & Clark, S. J. Genomic profiling of CpG methylation and allelic specificity using 
quantitative high-throughput mass spectrometry: critical evaluation and improvements. Nucleic Acids Res. 35, e119 (2007).
 69. Claus, R. et al. Quantitative DNA methylation analysis identifies a single CpG dinucleotide important for ZAP-70 expression and 
predictive of prognosis in chronic lymphocytic leukemia. J. Clin. Oncol. 30, 2483–91 (2012).
 70. Polak, J. F. et al. Carotid-Wall Intima–Media Thickness and Cardiovascular Events. N. Engl. J. Med. 365, 213–221 (2011).
 71. Akbaraly, T. N. et al. Adherence to healthy dietary guidelines and future depressive symptoms: evidence for sex differentials in the 
Whitehall II study. Am. J. Clin. Nutr. 97, 419–427 (2013).
 72. Agatston, A. S. et al. Quantification of coronary artery calcium using ultrafast computed tomography. J. Am. Coll. Cardiol. 15, 
827–832 (1990).
 73. Muntendam, P., McCall, C., Sanz, J., Falk, E. & Fuster, V. The BioImage Study: Novel approaches to risk assessment in the primary 
prevention of atherosclerotic cardiovascular disease–study design and objectives. American Heart Journal 160, (2010).
 74. Aryee, M. J. et al. Minfi: a flexible and comprehensive Bioconductor package for the analysis of Infinium DNA methylation 
microarrays. Bioinformatics 30, 1363–9 (2014).
 75. Leek, J. T., Johnson, W. E., Parker, H. S., Jaffe, A. E. & Storey, J. D. The sva package for removing batch effects and other unwanted 
variation in high-throughput experiments. Bioinformatics 28, 882–883 (2012).
Acknowledgements
This work was partly funded by the Flaviola research consortium of the European Union (FP7-KBBE-2008-2B) 
and the Strategic Action for Research in Health sciences (CP12/03080 and PI15/00071), which is an initiative 
from Carlos III Health Institute Madrid and the Spanish Ministry of Economy and Competitiveness and is 
co-funded with European Funds for Regional Development (FEDER). The AWHS was co-funded by the local 
Government of Aragon (Spain) through the Institute for Health Sciences of Aragon and the National Center 
for Cardiovascular Research at the Carlos III Health Institute in Madrid. The authors also acknowledge funding 
from the Research Committee of the Medical Faculty of Heinrich-Heine University Dusseldorf (grant number 
9772574). The authors are participants of the EU-funded COST Action CMST COST Action CM1406 EPICHEM 
(Epigenetic Chemical Biology), FA1403 POSITIVe (interindividual variation in response to consumption of plant 
food bioactives and determinants involved) and CA16112 NUTREDOX (Personalized Nutrition in aging society: 
redox control of major age-related diseases).
Author Contributions
W.V.B., C.H., A.M.M., M.T.P., K.H. conceived and designed the research; C.H. and A.M.M. coordinated the 
clinical sampling of NCT01799005 & NCT02174133; G.I., K.D., K.S.S. performed the wet lab experiments, 
G.I., K.D., M.T.P., W.V.B. performed statistical analysis; W.V.B., G.H., K.H., C.H., A.R.R. handled funding and 
supervision; G.I., K.D., M.P., K.S.S., M.T.P., C.G., C.H., A.R.M., W.V.B. acquired the data; G.I., K.D., K.S.S., M.T.P., 
W.V.B. drafted the manuscript; G.I., K.D., K.S.S., M.P., C.G., C.H., A.R.R., W.V.B. made critical revision of the 
manuscript for key intellectual content; V.L.T., M.L.L., J.A.S. coordinated and performed the AWHS study. G.I. 
and K.D. contributed equally to this work.
Additional Information
Supplementary information accompanies this paper at doi:10.1038/s41598-017-03434-0
Competing Interests: The authors declare that they have no competing interests.
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2017
